Megan Sheehan1, Brandie Heald2, Courtney Yanda3, Erinn Downs Kelly4, Stephen Grobmyer3, Charis Eng2, Matthew Kalady5, Holly Pederson3. 1. Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA. 2. Cleveland Clinic, Genomic Medicine Institute, Cleveland, OH, USA. 3. Cleveland Clinic, Breast Services Department, Cleveland, OH, USA. 4. Cleveland Clinic, RJ Tomsich Pathology and Laboratory Medicine Institute, Cleveland, OH, USA. 5. Cleveland Clinic, Department of Colorectal Surgery, Cleveland, OH, USA.
Abstract
OBJECTIVE: Lynch syndrome is an inherited genetic disorder associated with a predisposition to early-onset colorectal and endometrial cancers, but breast cancer risk in these patients is debated. The aim of this study is to evaluate breast cancer rates in a cohort of Lynch syndrome patients, as well as to identify women who may be eligible for additional breast cancer specific genetic testing or enhanced breast surveillance (contrast-enhanced magnetic resonance imaging (MRI) screening). MATERIALS AND METHODS: Using a hereditary colorectal cancer registry at a single academic institution for identification of patients with Lynch syndrome, a retrospective chart review was performed of 188 women with DNA mismatch repair (MMR) mutations. The Tyrer-Cuzick model was used to estimate breast cancer risk in patients without breast cancer. RESULTS: The prevalence of breast cancer differed based on mutation type (p=0.0043), as 27% of women with a PMS2 mutation were diagnosed with breast cancer, compared to 3%, 4%, and 9% in MLH1, MSH2, and MSH6 patients. The average age at diagnosis for women with a PMS2 mutation was 46.7 years. Additionally, 7.5% of unaffected women had an estimated lifetime risk of breast cancer greater than 20%. 46/188 (24.4%) of patients were eligible for breast specific genetic testing. CONCLUSION: Our analysis suggests that Lynch syndrome patients with PMS2 mutations may be at higher risk of developing breast cancer. Additionally, the personal and family history of cancer suggests crossover in eligibility for breast specific genetic testing in a significant number of patients (16.5-24.4%). Also, many women are eligible for enhanced breast surveillance (7.5%) which would otherwise not be offered.
OBJECTIVE: Lynch syndrome is an inherited genetic disorder associated with a predisposition to early-onset colorectal and endometrial cancers, but breast cancer risk in these patients is debated. The aim of this study is to evaluate breast cancer rates in a cohort of Lynch syndrome patients, as well as to identify women who may be eligible for additional breast cancer specific genetic testing or enhanced breast surveillance (contrast-enhanced magnetic resonance imaging (MRI) screening). MATERIALS AND METHODS: Using a hereditary colorectal cancer registry at a single academic institution for identification of patients with Lynch syndrome, a retrospective chart review was performed of 188 women with DNA mismatch repair (MMR) mutations. The Tyrer-Cuzick model was used to estimate breast cancer risk in patients without breast cancer. RESULTS: The prevalence of breast cancer differed based on mutation type (p=0.0043), as 27% of women with a PMS2 mutation were diagnosed with breast cancer, compared to 3%, 4%, and 9% in MLH1, MSH2, and MSH6 patients. The average age at diagnosis for women with a PMS2 mutation was 46.7 years. Additionally, 7.5% of unaffected women had an estimated lifetime risk of breast cancer greater than 20%. 46/188 (24.4%) of patients were eligible for breast specific genetic testing. CONCLUSION: Our analysis suggests that Lynch syndrome patients with PMS2 mutations may be at higher risk of developing breast cancer. Additionally, the personal and family history of cancer suggests crossover in eligibility for breast specific genetic testing in a significant number of patients (16.5-24.4%). Also, many women are eligible for enhanced breast surveillance (7.5%) which would otherwise not be offered.
Authors: Michael D Walsh; Daniel D Buchanan; Margaret C Cummings; Sally-Ann Pearson; Sven T Arnold; Mark Clendenning; Rhiannon Walters; Diane M McKeone; Amanda B Spurdle; John L Hopper; Mark A Jenkins; Kerry D Phillips; Graeme K Suthers; Jill George; Jack Goldblatt; Amanda Muir; Kathy Tucker; Elise Pelzer; Michael R Gattas; Sonja Woodall; Susan Parry; Finlay A Macrae; Robert W Haile; John A Baron; John D Potter; Loic Le Marchand; Bharati Bapat; Stephen N Thibodeau; Noralane M Lindor; Michael A McGuckin; Joanne P Young Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Elaine F Harkness; Emma Barrow; Katy Newton; Kate Green; Tara Clancy; Fiona Lalloo; James Hill; D Gareth Evans Journal: J Med Genet Date: 2015-06-22 Impact factor: 6.318
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Sanne W ten Broeke; Richard M Brohet; Carli M Tops; Heleen M van der Klift; Mary E Velthuizen; Inge Bernstein; Gabriel Capellá Munar; Encarna Gomez Garcia; Nicoline Hoogerbrugge; Tom G W Letteboer; Fred H Menko; Annika Lindblom; Arjen R Mensenkamp; Pal Moller; Theo A van Os; Nils Rahner; Bert J W Redeker; Rolf H Sijmons; Liesbeth Spruijt; Manon Suerink; Yvonne J Vos; Anja Wagner; Frederik J Hes; Hans F Vasen; Maartje Nielsen; Juul T Wijnen Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Debra L Monticciolo; Mary S Newell; Linda Moy; Bethany Niell; Barbara Monsees; Edward A Sickles Journal: J Am Coll Radiol Date: 2018-01-19 Impact factor: 5.532
Authors: Fergus J Couch; Hermela Shimelis; Chunling Hu; Steven N Hart; Eric C Polley; Jie Na; Emily Hallberg; Raymond Moore; Abigail Thomas; Jenna Lilyquist; Bingjian Feng; Rachel McFarland; Tina Pesaran; Robert Huether; Holly LaDuca; Elizabeth C Chao; David E Goldgar; Jill S Dolinsky Journal: JAMA Oncol Date: 2017-09-01 Impact factor: 31.777
Authors: Christina Therkildsen; Steen Ladelund; Lars Smith-Hansen; Lars Joachim Lindberg; Mef Nilbert Journal: Br J Cancer Date: 2017-10-24 Impact factor: 7.640
Authors: Maegan E Roberts; Sarah A Jackson; Lisa R Susswein; Nur Zeinomar; Xinran Ma; Megan L Marshall; Amy R Stettner; Becky Milewski; Zhixiong Xu; Benjamin D Solomon; Mary Beth Terry; Kathleen S Hruska; Rachel T Klein; Wendy K Chung Journal: Genet Med Date: 2018-01-18 Impact factor: 8.822
Authors: Jamie E Clarke; Stephanie Magoon; Irman Forghani; Francesco Alessandrino; Gina D'Amato; Emily Jonczak; Ty K Subhawong Journal: Eur J Radiol Open Date: 2022-04-25
Authors: Alejandra Padua-Bracho; José A Velázquez-Aragón; Verónica Fragoso-Ontiveros; Paulina María Nuñez-Martínez; María de la Luz Mejía Aguayo; Yuliana Sánchez-Contreras; Miguel Angel Ramirez-Otero; Marcela Angélica De la Fuente-Hernández; Silvia Vidal-Millán; Talia Wegman-Ostrosky; Abraham Pedroza-Torres; Cristian Arriaga-Canon; Luis A Herrera-Montalvo; Rosa Maria Alvarez-Gómez Journal: Int J Mol Sci Date: 2022-09-30 Impact factor: 6.208